Respiratory effects of buprenorphine/naloxone alone and in combination with diazepam in naive and tolerant rats

Toxicology Letters

Volumn 228, Issue 2, 2014, Pages 75-84

  Cohier, Camille ^a,b   Chevillard, Lucie ^a,b   Risède, Patricia ^a,b   Roussel, Olivier ^a,b,c   Mégarbane, Bruno ^a,b,d  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c IRCGN   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Buprenorphine; Diazepam; Naloxone; Respiratory depression; Whole body plethysmography

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; DIAZEPAM; FLUMAZENIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BODY PLETHYSMOGRAPH; BODY PLETHYSMOGRAPHY; BREATHING RATE; CONTROLLED STUDY; DRUG FORMULATION; DRUG TOLERANCE; EXPERIMENTAL STUDY; NONHUMAN; OPIATE ADDICTION; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RAT; RESPIRATION DEPRESSION; RESPIRATORY FUNCTION; RESPIRATORY TRACT PARAMETERS; TIDAL VOLUME;

BUPRENORPHINE; DIAZEPAM; NALOXONE; RESPIRATORY DEPRESSION; WHOLE-BODY PLETHYSMOGRAPHY;

ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; ANIMALS; BUPRENORPHINE; DIAZEPAM; DRUG INTERACTIONS; DRUG TOLERANCE; HYPNOTICS AND SEDATIVES; MALE; NALOXONE; NARCOTIC ANTAGONISTS; PLETHYSMOGRAPHY, WHOLE BODY; RATS; RATS, SPRAGUE-DAWLEY; RESPIRATORY INSUFFICIENCY;

EID: 84901020060     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2014.04.009     Document Type: Article

References (59)

1. Amass L., Pukeleviciene V., Subata E., et al. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals. Addiction 2012, 107:142-151.
2. Baraban S.C., Stornetta R.L., Guyenet P.G. Respiratory control of sympathetic nerve activity during naloxone-precipitated morphine withdrawal in rats. J. Pharmacol. Exp. Ther. 1993, 265:89-95.
3. Bazazi A.R., Yokell M., Fu J.J., et al. Illicit use of buprenorphine/naloxone among injecting and non injecting opioid users. J. Addict. Med. 2011, 5:175-180.
4. Belenky G.L., Holaday J.W. The opiate antagonist naloxone modifies the effects of electroconvulsive shock (ECS) on respiration, blood pressure and heart rate. Brain Res. 1979, 177:414-417.
5. Belzung C., Agmo A. Naloxone potentiates the effects of subeffective doses of anxiolytic agents in mice. Eur. J. Pharmacol. 1997, 323:133-136.
6. Bruce R.D., Govindasamy S., Sylla L., et al. Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market. Am. J. Drug Alcohol Abuse 2009, 35:68-72.
7. Chevillard L., Mégarbane B., Risède P., et al. Characteristics and comparative severity of respiratory response to toxic doses of fentanyl, methadone, morphine, and buprenorphine in rats. Toxicol. Lett. 2009, 191:327-340.
8. Comer S.D., Sullivan M.A., Vosburg S.K., et al. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction 2010, 105:709-718.
9. Comer S.D., Collins E.D. Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. J. Pharmacol. Exp. Ther. 2002, 303:695-703.
10. Dai S., Wong C.Y., Ogle C.W. Antagonism of pentobarbitone-induced respiratory depression by naloxone in rats. Pharmacology 1983, 27:197-201.
11. Daulouède J.P., Caer Y., Galland P., et al. Preference for buprenorphine/naloxone and buprenorphine among patients receiving buprenophine maintenance therapy in France: a prospective, multicenter study. J. Subst. Abuse Treat. 2009, 38:83-89.
12. Degenhardt L., Larance B., Bell J., et al. Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation. Med. J. Aust. 2009, 19:161-165.
13. Demetrovics Z., Farkas J., Csorba J., et al. Early experience with suboxone maintenance therapy in Hungary. Neuropsychopharmacol. Hung. 2009, 11:249-257.
14. Duke A.N., Correia C.J., Walsh S.L., et al. Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers. Psychopharmacology (Berlin) 2010, 11:303-312.
15. Elkader A., Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin. Pharmacokinet. 2005, 44:661-680.
16. Emmerson P.J., Liu M.R., Woods J.H., et al. Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J. Pharmacol. Exp. Ther. 1994, 271:1630-1637.
17. Fiellin D.A., Rosenheck R.A., Kosten T.R. Office-based treatment for opioid dependence: reaching new patient populations. Am. J. Psychiatry 2001, 158:1200-1204.
18. Fiellin D.A., Friedland G.H., Gourevitch M.N. Opioid dependence: rationale for and efficacy of existing and new treatments. Clin. Infect. Dis. 2006, 43:173-177.
19. Gellert V.F., Holtzman S.G. Development and maintenance of morphine tolerance and dependence in the rat by scheduled access to morphine drinking solutions. J. Pharmacol. Exp. Ther. 1978, 205:536-546.
20. Glover E.M., Davis M. Anxiolytic-like effects of morphine and buprenorphine in the rat model of fear-potentiated startle: tolerance, cross-tolerance, and blockade by naloxone. Psychopharmacology (Berlin) 2008, 198:167-180.
21. Grecksch G., Bartzsch K., Widera A., et al. Development of tolerance and sensitization to different opioid agonists in rats. Psychopharmacology (Berlin) 2006, 186:177-184.
22. Gueye P.N., Borron S.W., Risede P., Monier C., et al. Lack of effect of single high doses of buprenorphine on arterial blood gases in the rat. Toxicol. Sci. 2001, 62:148-154.
23. Gueye P.N., Borron S.W., Risede P., et al. Buprenorphine and midazolam act in combination to depress respiration in rats. Toxicol. Sci. 2002, 65:107-114.
24. Häkkinen M., Heikman P., Ojanperä I. Parenteral buprenorphine-naloxone abuse is a major cause of fatal buprenorphine-related poisoning. Forensic Sci. Int. 2013, 232:11-15.
25. Häkkinen M., Launiainen T., Vuori E., et al. Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning. Eur. J. Clin. Pharmacol. 2012, 68:301-309.
26. Harris D.S., Jones R.T., Welm S., et al. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend. 2000, 61:85-94.
27. Isom G.E., Elshowihy R.M. Naloxone-induced enhancement of carbon dioxide stimulated respiration. Life Sci. 1982, 31:113-118.
28. Jones J.D., Mogali S., Comer S.D. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012, 125:8-18.
29. Larance B., Degenhardt L., Lintzeris N., et al. Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing. Drug Alcohol Depend. 2011, 118:265-273.
30. Lintzeris N., Nielsen S. Benzodiazepines, methadone and buprenorphine: interactions and clinical management. Am. J. Addict. 2010, 19:59-72.
31. Malin D.H., Leavell J.G., Freeman K., et al. Continuous infusion of naloxone: effects on behavior and oxygen consumption. Pharmacol. Biochem. Behav. 1985, 22:791-795.
32. Martin H.A. The possible consequences of combining Lorazepam and buprenorphine/naloxone: a case review. J. Emerg. Nurs. 2011, 37:200-202.
33. McCormick G.Y., White W.J., Zagon I.S., et al. Effects of diazepam on arterial blood gas concentrations and ph of adult rats acutely and chronically exposed to methadone. J. Pharmacol. Exp. Ther. 1984, 230:353-359.
34. Mégarbane B., Buisine A., Jacobs F., et al. Prospective comparative assessment of buprenorphine overdose with heroin and methadone: clinical characteristics and response to antidotal treatment. J. Subst. Abuse Treat. 2010, 38:403-407.
35. Mendelson J., Jones R.T. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment. Drug Alcohol Depend. 2003, 70:29-37.
36. Mendez I.A., Trujillo K.A. NMDA receptor antagonists inhibit opiate antinociceptive tolerance and locomotor sensitization in rats. Psychopharmacology 2008, 196:497-509.
37. Monte A.A., Mandell T., Wilford B.B., et al. Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence. J. Addict. Dis. 2009, 28:226-233.
38. Nielsen S., Taylor D.A. The effect of buprenorphine and benzodiazepines on respiration in the rat. Drug Alcohol Depend. 2005, 79:95-101.
39. Nigam A.K., Srivastava R.P., Saxena S., et al. Naloxone-induced withdrawal in patients with buprenorphine dependence. Addiction 1994, 89:317-320.
40. Olson E.B. Naloxone accelerates the rate of ventilatory acclimatization to hypoxia in awake rats. Life Sci. 1987, 41:161-167.
41. Orman J.S., Keating G.M. Spotlight on buprenorphine/naloxone in the treatment of opioid dependence. CNS Drugs 2009, 23:899-902.
42. Pedapati E.V., Bateman S.T. Toddlers requiring pediatric intensive care unit admission following at-home exposure to buprenorphine/naloxone. Pediatr. Crit. Care Med. 2011, 12:102-107.
43. Preston K.L., Bigelow G.E., Liebson I.A. Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology (Berlin) 1988, 94:484-490.
44. Raynor K., Kong H., Chen Y., et al. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol. Pharmacol. 1994, 45:330-334.
45. Rich J.D., McKenzie M., Dickman S., et al. An adverse reaction to buprenorphine/naloxone induction in prison: a case report. Addict. Disord. Addict. Treat. 2011, 10:199-200.
46. Robinson G.M., Dukes P.D., Robinson B.J., et al. The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand. Drug Alcohol Depend. 1993, 33:81-86.
47. Sawynok J., Pinsky C., LaBella F.S. On the specificity of naloxone as an opiate antagonist. Life Sci. 1979, 25:1621-1632.
48. Schlenker E.H., Martin D.S., Lin X.M., et al. Naloxone microinjected into the arcuate nucleus has differential effects on ventilation in male and female rats. Physiol. Behav. 1997, 62:531-536.
49. Simojoki K., Vorma H., Alho H. A retrospective evaluation of patients switched from buprenorphine (Subutex) to the buprenorphine/naloxone combination (Suboxone). Subst. Abuse Treat. Prev. Policy 2008, 3:16.
50. Smirnov A., Kemp R. Use and misuse of opioid replacement therapies: a Queensland study. Subst. Use Misuse 2012, 47:78-85.
51. Steinbrook R.A., Feldman H.A., Fencl V., et al. Naloxone does not affect ventilatory responses to hypoxia and hypercapnia in rats. Life Sci. 1984, 34:881-887.
52. Stimolo C., Favero V.D., Zecchinato G., et al. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre. Clin. Drug Invest. 2010, 30:27-31.
53. Strain E.C., Stoller K., Walsh S.L., et al. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. Psychopharmacology 2000, 148:374-383.
54. Svensson A.I., Berntsson A., Eirefelt M., et al. Naloxone antagonizes GABA(A)/benzodiazepine receptor function in rat corticohippocampal synaptoneurosomes. J. Neural Transm. 2000, 107:261-270.
55. Uosukainen H., Pentikäinen H., Tacke U. The effect of an electronic medicine dispenser on diversion of buprenorphine-naloxone-experience from a medium-sized Finnish city. J. Subst. Abuse Treat. 2013, 45:143-147.
56. Vicknasingam B., Mazlan M., Schottenfeld R.S., et al. Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia. Drug Alcohol Depend. 2010, 111:44-49.
57. Walker E.A., Young A.M. Differential tolerance to antinociceptive effects of mu opioids during repeated treatment with etonitazene, morphine, or buprenorphine in rats. Psychopharmacology (Berlin) 2001, 154:131-142.
58. Williams J.T., Ingram S.L., Henderson G., et al. Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol. Rev. 2013, 65:223-254.
59. Yassen A., Olofsen E., Romberg R., et al. Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. Clin. Pharmacol. Ther. 2007, 81:50-58.